<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02732054</url>
  </required_header>
  <id_info>
    <org_study_id>Research ID: 02891</org_study_id>
    <nct_id>NCT02732054</nct_id>
  </id_info>
  <brief_title>Hepatitis B Vaccination in HIV-infected Adults With Low CD4 Cell Counts</brief_title>
  <official_title>Comparison of Immunogenicity and Safety of 4 Standard Doses and 3 Standard Doses of Hepatitis B Vaccination in HIV-infected Adults Who Have CD4 &lt; 200 Cells/mm3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiang Mai University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiang Mai University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to evaluate the efficacy of different hepatitis B vaccination regimens in
      HIV-infected adults with low CD4 cell count in northern Thailand.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-infected adults with CD4+ cell counts &lt; 200 cells/mm3, undetectable plasma HIV-1 RNA, and
      negative for all HBV markers were randomly assigned to receive one of these 2 regimens of
      recombinant hepatitis B vaccine (Centro De Ingenieria Genetica Y Biotecnologia, La Habana,
      Cuba); 1) 20 μg IM at months 0, 1, and 6 (3-standard doses group), and 2) 20 μg IM at months
      0, 1, 2, 6 (4-standard doses group).

      This study aimed to evaluate the efficacy and safety of these 2 hepatitis B vaccination
      regimens at month 7 after vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with protective immunity against HBV</measure>
    <time_frame>1 month after vaccination</time_frame>
    <description>comparison of proportion of participants who had protective immunity (anti-HBS titer &gt;=10 mIU/ml) against HBV between HIV group 2 v.s. HIV group 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The geometric means of anti-HBs titers</measure>
    <time_frame>1 month after vaccination</time_frame>
    <description>Comparison of the geometric means of anti-HBS titers between HIV group 2 v.s. HIV group 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with high level of immune response against HBV</measure>
    <time_frame>1 month after vaccination</time_frame>
    <description>Comparison of proportion of participants who had anti-HBS titers &gt;= 100 mIU/ml between HIV group 2 v.s. HIV group 1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>HIV-Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receiving three intramuscular injections of 20 µg of recombinant hepatitis B vaccine [(CIGB) La Habana, Cuba] at months 0, 1, and 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receiving four intramuscular injections of 20 µg of recombinant hepatitis B vaccine [(CIGB) La Habana, Cuba] at months 0, 1, 2, and 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Hepatitis B vaccine [(CIGB) La Habana, Cuba]</intervention_name>
    <description>Different HBV vaccine regimen in each group</description>
    <arm_group_label>HIV-Group 1</arm_group_label>
    <arm_group_label>HIV-Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-infection

          2. ≥18 years old

          3. Received combination antiretroviral therapy for at least 1 year

          4. Had a CD4+ cell count &lt; 200 cells/mm3 for at least 1 year

          5. Undetectable plasma HIV-1 RNA for at least 1 year

          6. Negative for hepatitis B surface antigen (HBsAg), antibody to hepatitis B surface
             antigen (anti-HBs), and antibody to hepatitis B core antigen (anti-HBc),

          7. Had no history of previous HBV vaccine

          8. Negative for antibody to hepatitis C virus (anti-HCV)

          9. No active opportunistic infections (at the time of screening)

         10. Willing to sign an informed consent

         11. Able to return for follow-up.

        Exclusion criteria

          1. Pregnancy or lactation

          2. History of hypersensitivity to any component of the vaccine

          3. Active malignancy receiving chemotherapy or radiation, or other immunocompromised
             conditions besides HIV (e.g., solid organ transplant), received immunosuppressive
             (e.g., corticosteroid ≥ 0.5 mg/kg/day) or immunomodulating treatment in the last six
             months before screening visit

          4. Renal insufficiency (creatinine clearance &lt;30 mL/min)

          5. Decompensated cirrhosis (Child-Pugh class C)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Romanee Chaiwarith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thailand Maharaj Nakorn Chiang Mai Hospital, Department of Medicine, Chiang Mai University Muang, Chiang Mai Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai Hospital, Department of Medicine, Chiang Mai University</name>
      <address>
        <city>Muang</city>
        <state>Chiang Mai</state>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>April 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2016</study_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chiang Mai University</investigator_affiliation>
    <investigator_full_name>Romanee Chaiwarith</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>HBV vaccination, immunity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

